Unaudited Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Accumulated deficit	Noncontrolling interests	Total
Beginning balance (in shares) at Dec. 31, 2021						8,700,885
Beginning balance at Dec. 31, 2021						$ 107,808
Ending balance (in shares) at Mar. 31, 2022						8,700,885
Ending balance at Mar. 31, 2022						$ 107,808
Beginning balance (in shares) at Dec. 31, 2021	2,059,072
Beginning balance at Dec. 31, 2021	$ 2	$ 816		$ (96,997)	$ 14,395	(81,784)
Stockholders' Equity (Deficit)
Exercise of stock options (in shares)	2,572
Stock-based compensation		89				89
Unrealized loss on marketable securities			$ (158)			(158)
Net loss				(11,312)		(11,312)
Ending balance (in shares) at Mar. 31, 2022	2,061,644
Ending balance at Mar. 31, 2022	$ 2	905	(158)	(108,309)	14,395	$ (93,165)
Beginning balance (in shares) at Dec. 31, 2022						8,700,885
Beginning balance at Dec. 31, 2022						$ 107,808
Convertible preferred stock
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)						(8,700,885)
Conversion of convertible preferred stock and non-controlling interests to common stock						$ (107,808)
Beginning balance (in shares) at Dec. 31, 2022	2,217,737
Beginning balance at Dec. 31, 2022	$ 2	1,197	(41)	(158,223)	14,395	(142,670)
Stockholders' Equity (Deficit)
Stock-based compensation		265				265
Unrealized loss on marketable securities			177			177
Issuance of common stock for cash in pre-closing financing (in shares)	3,730,608
Issuance of common stock for cash in pre-closing financing	$ 4	30,636				30,640
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)	5,059,338
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability	$ 5	42,442				42,447
Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)	10,374,272
Issuance of common stock to Sesen Bio shareholders in reverse capitalization	$ 10	72,034				72,044
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)	18,872,711
Conversion of convertible preferred stock and non-controlling interests to common stock	$ 19	122,185			$ (14,395)	107,809
Net loss				(24,642)		(24,642)
Ending balance (in shares) at Mar. 31, 2023	40,254,666
Ending balance at Mar. 31, 2023	$ 40	$ 268,759	$ 136	$ (182,865)		$ 86,070